ArticleJournal of community genetics2020
Determining accurate costs for genomic sequencing technologies-a necessary prerequisite.
Article in Journal of community genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Data-Related and Methodological Challenges in Assessing the Cost-Effectiveness of Traditional and Genomic Newborn Screening Programs.Applied health economics and health policy · 2026Review
- Analytical Validation of a Genomic Newborn Screening Workflow.International journal of neonatal screening · 2025Article
- Article
- Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada.JAMA network open · 2024Article
- Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine.Genes · 2024Review
- Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia.BMJ open · 2023Article
- Test development, optimization and validation of a WGS pipeline for genetic disorders.BMC medical genomics · 2023Article
- Correspondence on "Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions" by Lavelle et al.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.Frontiers in oncology · 2022Review
- The Economic, Medical and Psychosocial Consequences of Whole Genome Sequencing for the Genetic Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study Protocol.Frontiers in genetics · 2022Article
- Incorporating Cascade Effects of Genetic Testing in Economic Evaluation: A Scoping Review of Methodological Challenges.Children (Basel, Switzerland) · 2021Article
- Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Streamlining Quantitative Analysis of Long RNA Sequencing Reads.International journal of molecular sciences · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Genome sequencing (GS) is increasingly being translated into clinical practice and is a technology characterized by a complex multi-step workflow. Funding decisions for GS would be aided by formal economic evaluation of GS platforms, but these analyses require detailed costing. This article addresses the importance of and challenges associated with costing GS using a GS microcosting project in autism spectrum disorder as an illustrative example.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.